Clinical Trial Update: A Phase II Study of Toripalimab Plus Chemotherapy and Low-Dose Radiotherapy for Neoadjuvant Therapy-Refractory Esophageal Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

This is a Phase II trial evaluating toripalimab in combination with chemotherapy and low-dose radiotherapy as neoadjuvant therapy for esophageal squamous cell c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Toripalimab (Toripalimab)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Esophageal Squamous Cell Carcinoma (ESCC) | Phase 2 | Status: NOT_YET_RECRUITING